KRAS and neoplasm: This loss of KRAS G12C could be due to the sensitivity threshold of the NGS assay or, alternatively, a reversion to the wild type, which has also been described in colorectal cancer, whereby loss of this mutation is a mechanism the tumor uses to escape immune detection [16].